Screening to prevent polyoma virus nephropathy: A medical decision analysis

American Journal of Transplantation

Volumn 5, Issue 10, 2005, Pages 2410-2416

  Kiberd, Bryce A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

BK virus; Cost effectiveness; Economic analysis; Kidney transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ARTICLE; BK VIRUS; CHRONIC GRAFT REJECTION; COMPUTER SIMULATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MEDICAL DECISION MAKING; MEDLINE; POLYOMA VIRUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; SCREENING; VIREMIA; VIRUS INFECTION; ADOLESCENT; ADULT; COMPUTER PROGRAM; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE COURSE; GRAFT REJECTION; INCIDENCE; KIDNEY; MASS SCREENING; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT OUTCOME; VIROLOGY;

ADOLESCENT; ADULT; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY TRANSPLANTATION; MASS SCREENING; MEDLINE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYOMAVIRUS; POLYOMAVIRUS INFECTIONS; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY; SOFTWARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644675622     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01034.x     Document Type: Article

References (44)

1. Mannon RB. Polyomavirus nephropathy: what have we learned¿ Transplantation 2004 77 : 1313 1318.
2. Fishman JA. BK virus nephropathy-polyomavirus adding insult to injury. N Engl J Med 2002 347 : 527 530.
3. Gardner SD Field AM Coleman DV et al. New human papovavirus (BK) isolated from urine after transplantation. Lancet 1971 1 : 1253 1257.
4. Padgett BL Walker DL ZuRhein GM et al. Cultivation of papova-like virus from human brain with progressive leukoencephalopathy. Lancet 1971 1 : 1257 1260.
5. Hogan TF Borden EC McBain JA Padgett BL Walker DL. Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med 1980 92 : 373 378.
6. Binet I Nickeleit V Hirsch HH et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999 67 : 918 922.
7. Baksh FK Finkelstein SD Swalsky PA Stoner GL Ryschkewitsch CF Randhawa P. Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am J Kidney Dis 2001 38 : 354 365.
8. Ramos E Drachenberg CB Papadimitriou JC et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002 13 : 2145 2151.
9. Hirsch HH Knowles W Dickenmann M et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002 347 : 488 496.
10. Celik B Shapiro R Vats A Randhawa PS. Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant 2003 3 : 1378 1382.
11. Vats A Shapiro R Singh Randhawa P et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003 75 : 105 112.
12. Luke PPW Jevnikar AM McAlister VC et al. One year follow up of renal allograft recipients with BK virus associated nephropathy treated with intravenous immunoglobulin. Am J Transplant 2004 4 ( Suppl 8 201.
13. Josephson MA Kadambi PV Javaid B et al. The use of leflunomide in virally infected transplant patients (Abstract). J Am Soc Nephrol 2004 15 : 523A.
14. Nickeleit V Singh HK Mihatsch MJ. Polyomavirus nephropathy: morphology, pathophysiology, and clinical management. Curr Opin Nephrol Hypertens 2003 12 : 599 605.
15. Brennan DC Agha IA Bohl D et al. Incidence of BK with tacrolimus versus cyclosporine and the impact of preemptive immunosuppression reduction. Am J Transplant 2005 5 : 582 594.
16. Randhawa PS Finkelstein S Scantlebury V et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999 67 : 103 109.
17. Nickeleit V Klimkait T Binet IF et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000 342 : 1309 1315.
18. United Network of Organ Sharing http://www.unos.org/
19. United States Renal Data System. http://www.usrds.org/
20. Razonable RR Brown RA Humar A Covington E Alecock E Paya CV, The PV16000 Study Group. Human polyomavirus infection is common in cytomegalovirus D+/R- solid organ transplant recipients. Am J Transplant 2004 4 ( Suppl 8 338.
21. Kaufman DB Shapiro R Lucey MR Cherikh WS Bustami RT Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004 4 ( Suppl 9 38 54.
22. Thomas A Geetha D. Outcome of BK virus associated nephropathy following reduction in immunosuppression. Am J Transplant 2004 4 ( Suppl 8 201.
23. Knoll GA MacDonald I Khan A Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003 14 : 2381 2386.
24. Pelletier RP Akin B Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003 17 : 200 205.
25. Schnuelle P van der Heide JH Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002 13 : 536 543.
26. Vanrenterghem Y van Hooff JP Squifflet JP et al. European Tacrolimus/MMF Renal Transplantation Study Group. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 2005 5 : 87 95.
27. Prommool S Jhangri GS Cockfield SM Halloran PF. Time dependency of factors affecting renal allograft survival. J Am Soc Nephrol 2000 11 : 565 573.
28. Meier-Kriesche HU Kaplan B. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. Am J Transplant 2002 2 : 100 104.
29. Meier-Kriesche HU Steffen BJ Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003 75 : 1341 1316.
30. Ojo AO Meier-Kriesche HU Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000 69 : 2405 2409.
31. Yen EF Hardinger K Brennan DC et al. Cost-effectiveness of extending medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant 2004 4 : 1703 1708.
32. Schnitzler MA Whiting JF Brennan DC et al. The expanded criteria donor dilemma in cadaveric renal transplantation. Transplantation 2003 75 : 1940 1945.
33. Keown PA Kiberd B Balshaw R et al. An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation. Pharmacoeconomics 2004 22 : 621 632.
34. Keown PA Balshaw R Krueger H Baladi JF. Economic analysis of basiliximab in renal transplantation. Transplantation 2001 71 : 1573 1579.
35. Lorber MI Fastenau J Wilson D DiCesare J Hall ML. A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin Transplant 2000 14 : 479 485.
36. Hornberger JC Best JH Garrison LP Jr.. Cost-effectiveness of repeat medical procedures: kidney transplantation as an example. Med Decis Making 1997 17 : 363 372.
37. Whiting JF Transplantation Outcomes Research Group. Standards for economic and quality of life studies in transplantation. Transplantation 2000 70 : 1115 1121.
38. Gu ZY Li Q Si YL Li X Hao HJ Song HJ. Prevalence of BK virus and JC virus in peripheral blood leukocytes and normal arterial walls in healthy individuals in China. J Med Virol 2003 70 : 600 605.
39. Meier-Kriesche HU Schold JD Srinivas TR Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378 383.
40. Williams JW Javaid B Kadambi PV et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005 352 : 1157 1158.
41. Lalezari JP Stagg RJ Kuppermann BD et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997 126 : 257 263.
42. Wali RK Drachenberg C Hirsch HH et al. BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 2004 78 : 1069 1073.
43. Terasaki P Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004 4 : 438.
44. Schaffer D Langone A Nylander WA Kizilisik T Helderman JH. Reduced BK virus nephropathy but increased acute rejection with mycophenolate mofetil dose reduction in kidney transplantation. Am J Transplant 2004 4 ( Suppl 8 199.